-
SaNOtize moves to carve a new market demand: over-the-counter prevention
There are currently zero authorized or approved preventative COVID therapies in the U.S. but Canadian biotech SaNOtize wants to change that, charting plans to move a nasal spray into a phase 3 study as soon as October. It’s a deviation for the company that until now has been developing the nitric oxide nasal spray (NONS) as an early antiviral treatment, primarily assessing a reduction... -
SaNOtize raised $24M to fund phase 3 trial of COVID-19 nasal spray
SaNOtize has raised a $24 million series B round, giving it the cash to fund its ongoing phase 3 COVID-19 prevention trial and other research into its nitric oxide nasal spray (NONS). The Vancouver-based company set up shop in 2017 to unlock the antimicrobial properties of nitric oxide. Using its nitric oxide releasing solution platform, SaNOtize sought to enable the use of the molecule in... -
Clinical Study Suggests SaNOtize Nitric Oxide Nasal Spray Is Effective at Preventing COVID-19 after High-Risk Exposure
Published on May 11, 2022 on Businesswire.com. After confirmed exposure to COVID-19, infection rate in participants (n=625) who took NONS™ was 6.4% versus 25.6% in the control group (P<0.0001). The new data build upon previously reported Phase III trial results demonstrating that a rapid reduction of viral load prevents progression to infection after COVID-19 exposure. The new study, conducted at Srinakharinwirot University in Bangkok,... -
Phase 3 Clinical Trial Confirms SaNOtize’s Treatment is 99% Effective Against COVID-19
SaNOtize and Glenmark Pharmaceuticals Limited has announced on February 09, 2022: Phase 3 trial reached primary endpoint and demonstrated a reduction in SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more than 99% in 48 hours Treatment also demonstrated, in the high-risk group (n=218), a greater proportion of patients who achieved a combination of clinical... -
Outstanding Preliminary Results of A Clinical Trial Treating Moderate-To-Severe Covid-19 Patients, Conducted By Amorphical, An Israeli Biotechnology Company
Amorphical, an Israeli biotech company developing Amorphous Calcium Carbonate (ACC) has announced results of a phase II clinical trial. Amorphical’s Novel COVID-19 Amorphous Calcium Carbonate (ACC) Treatment Significantly Reduces the Risk of ICU Admission and Mortality in Interim Analysis of a Phase II Study Involving Patients Hospitalized with Moderate-to-Severe COVID-19. (NIH Clinical Trial Registration No. NCT04900337) Published by Amorphical, Ness Ziyona, Israel
